Literature DB >> 8347960

Three-dimensional MR imaging and display of intracranial disease: improvements with the MP-RAGE sequence and gadolinium.

M N Brant-Zawadzki1, G D Gillan, D J Atkinson, N Edalatpour, M Jensen.   

Abstract

Three-dimensional (3D) image rendering was performed in 14 patients who had undergone magnetic resonance (MR) imaging for focal brain lesions. The MR study included the magnetization-prepared rapid gradient-echo (MP-RAGE) sequence with 64 or 128 partitions. Resultant contiguous sections 2.5 or 1.25 mm thick, respectively, were obtained. Images were acquired before and after administration of gadopentetate dimeglumine. Resultant 3D data sets were processed on a commercially available workstation. Correlative surgical observation was performed in four cases. All data sets were successfully processed into 3D images. The precontrast images proved superior to gadolinium-enhanced images for brain surface rendering. Postcontrast images proved superior for reconstruction of tumors and vascular structures. The 64-partition data set proved sufficient for all postprocessing. Coronal orientation was preferred to sagittal orientation for surface rendering because it provided optimal orthogonal orientation of sulcal and gyral brain surface features. Three-dimensional rendition allowed easy superposition of lesion, brain, vessels, and scalp features--all useful for surgical planning. The central sulcus was easily recognized in the midline partitions and traced mediolaterally for projection on the cortical surface. MP-RAGE provides a 3D data set that can be obtained in just over 3 minutes, from which clinically useful 3D renderings are possible. The rapidity of acquisition and capability for 3D rendering provides additional clinical utility.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8347960     DOI: 10.1002/jmri.1880030416

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  5 in total

1.  Three-dimensional, T1-weighted gradient-echo imaging of the brain with a volumetric interpolated examination.

Authors:  Stephan G Wetzel; Glyn Johnson; Andrew G S Tan; Soonmee Cha; Edmond A Knopp; Vivian S Lee; David Thomasson; Neil M Rofsky
Journal:  AJNR Am J Neuroradiol       Date:  2002 Jun-Jul       Impact factor: 3.825

Review 2.  Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.

Authors:  Benjamin M Ellingson; Martin Bendszus; Jerrold Boxerman; Daniel Barboriak; Bradley J Erickson; Marion Smits; Sarah J Nelson; Elizabeth Gerstner; Brian Alexander; Gregory Goldmacher; Wolfgang Wick; Michael Vogelbaum; Michael Weller; Evanthia Galanis; Jayashree Kalpathy-Cramer; Lalitha Shankar; Paula Jacobs; Whitney B Pope; Dewen Yang; Caroline Chung; Michael V Knopp; Soonme Cha; Martin J van den Bent; Susan Chang; W K Al Yung; Timothy F Cloughesy; Patrick Y Wen; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2015-08-05       Impact factor: 12.300

3.  Retrograde cortical and deep venous drainage in patients with intracranial dural arteriovenous fistulas: comparison of MR imaging and angiographic findings.

Authors:  Mika Kitajima; Toshinori Hirai; Yukunori Korogi; Masayuki Yamura; Koichi Kawanaka; Ichiro Ikushima; Yoshiko Hayashida; Yasuyuki Yamashita; Junichi Kuratsu
Journal:  AJNR Am J Neuroradiol       Date:  2005 Jun-Jul       Impact factor: 3.825

4.  Evaluation of the intracranial dural sinuses with a 3D contrast-enhanced MP-RAGE sequence: prospective comparison with 2D-TOF MR venography and digital subtraction angiography.

Authors:  L Liang; Y Korogi; T Sugahara; M Onomichi; Y Shigematsu; D Yang; M Kitajima; Y Hiai; M Takahashi
Journal:  AJNR Am J Neuroradiol       Date:  2001-03       Impact factor: 3.825

5.  A T1-weighted rapid three-dimensional gradient-echo technique (MP-RAGE) in preoperative MRI of intracranial tumours.

Authors:  F Fellner; K Holl; P Held; C Fellner; R Schmitt; H Böhm-Jurkovic
Journal:  Neuroradiology       Date:  1996-04       Impact factor: 2.804

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.